Mark Fleming

Apr 4, 2024 | europeanurology.com | Florian Roghmann |Elena Fernandez |Elena Fernández |Mark Fleming |Virginia Oncology Associates

It has previously been estimated that FGFR3 gene mutation or fusion occurs in approximately 20% of patients with advanced lower tract urothelial cancer (LTUC) and up to 40–50% of patients with advanced upper tract urothelial cancer (UTUC) [1Ross J.S. Wang K. Khaira D. et al. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. , 2Necchi A. Madison R. Pal S.K. et al.